Market Data 
Markets
Replies to post #211932 on Biotech Values
06/17/17 10:19 AM
The meeting, which was led by OMB Director Mick Mulvaney and included top leadership of U.S. health agencies, trade officials and senior Trump advisors like Gary Cohn and Reed Cordish, ended with little agreement.
A White House spokesperson said only that the meeting is "part of the ongoing discussions to reduce the burden of the high cost of drug prescriptions and unleash a wave of innovation to develop cures and treatments for patients" [emphasis added].
...The administration is not discussing taking “broad action to curb drug pricing," analyst Terry Haines who follows Washington politics for investment bank EverCore ISI said Friday.
“If anything, the limited scope of the discussions should be good news for the pharmaceutical and bio industries and investors because nothing like sweeping action to curb drug prices is under discussion and the industry probably will not view the subjects of the Trump discussions…negatively.”
AI
